End of the road for Essure®?

Journal of Family Planning and Reproductive Health Care

Volumn 43, Issue 3, 2017, Pages 240-241

  Horwell, David H ^a  

^a Harpenden   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC REACTION; CONTRACEPTION; DEVICE MIGRATION; FALLOPIAN TUBE; FEMALE; FEMALE STERILIZATION; GENERAL ANESTHESIA; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; LETTER; MENORRHAGIA; MENSTRUAL IRREGULARITY; REOPERATION; SALPINGECTOMY; TUBAL OCCLUSION INSERT; UTERUS PERFORATION;

EID: 85021741942     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2017-101850     Document Type: Letter

References (4)

1. National Institute for Health and Care Excellence. Hysteroscopic Sterilisation by Tubal Cannulation and Placement of Intrafallopian Implants. Interventional Procedures Guidance [IPG315]. 2009 https://www. nice. org. uk/ guidance/ ipg315 (accessed 6 June 2017).
2. Sagili H, Divers M. Hysteroscopic sterilisation with Essure: A promising new alternative to tubal ligation J Fam Plann Reprod Health Care 2008;34:99-102.
3. Mao J, Pfeifer S, Schlegel P, et al. Safety and efficacy of hysteroscopic sterilization compared with laparoscopic sterilization: An observational cohort study. BMJ 2015;351:h5162.
4. U. S. Food and Drug Administration. FDA Activities: Essure. Updated 8 May 2017. https://www. fda. gov/ MedicalDevices/ ProductsandMedicalProcedures/ ImplantsandProsthetics/ EssurePermanentBirthControl/ ucm452254. htm (accessed 22 June 2017).